April 22, 2024 Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market Read more
April 22, 2024 Stockholm3 study awarded best abstract in the prostate cancer biopsy indication session at the 2024 European Association of Urology meeting Read more
April 8, 2024 Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Read more
April 4, 2024 AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit Read more
March 28, 2024 Flerie Invest AB erhåller FDI-godkännande för budpliktsbudet avseende Lipum AB (publ) Read more
March 27, 2024 Mendus announces ethics committee approval for the AMLM22-CADENCE trial with lead product vididencel in AML Read more
March 18, 2024 Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program Read more
March 15, 2024 Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3 Read more
March 15, 2024 Mendus AB (publ) – The exercise period for warrants of series TO3 commences today Read more
March 14, 2024 Symcel raises 86 MSEK to develop the world’s fastest detection system of live bacteria Read more
March 14, 2024 Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes Read more
March 6, 2024 Flerie Invest AB lämnar ett kontant budpliktsbud till aktieägarna och konvertibelinnehavaren i Lipum AB (publ) samt offentliggör erbjudandehandling Read more
March 1, 2024 Flerie Invest AB har ökat sitt innehav i Lipum AB (publ) varigenom gränsen för budplikt passerats Read more
March 1, 2024 Flerie Invest AB has increased its holding in Lipum AB (publ), whereby the limit for mandatory bidding has been exceeded Read more
February 12, 2024 Nanologica delivers NLAB SIV™ to a customer in Asia to a value of over MSEK 4 Read more
February 12, 2024 FDA Accepts Xpray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31st of July Read more
February 7, 2024 Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial Read more
January 30, 2024 Lipum reports positive interim results from clinical phase 1 study showing that SOL-116 reduces plasma BSSL levels in healthy subjects Read more
January 25, 2024 Synerkine Pharma appoints industry veteran Anders Ekblom to its Board of Directors Read more
January 17, 2024 AnaCardio receives second tranche of SEK 50 million, completing the previously announced Series A round Read more
January 15, 2024 XNK Therapeutics receives EMA scientific recommendation for evencaleucel as an Advanced Therapy Medicinal Product Read more